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There is ~ntroversy ahaot the mywardiat deprewnt 
effects of amiadamne in patients with decreawd cardiac 
function undergoing surgery. Some surgeons b&eve that 
these e5ects eompliite the diseonlinuation of cardiopulmo- 
nary bypass. Accordingly, the hemodynamic o&as of 
am,odwme “we cva,“s*ed in hyo gmmopr Of sllerthet&d 
mongrel dogs that had undergone a median stemo,cmy. 4 
control erwm al 10 do-a and an amiodamoe.treatod erooo 
(15 m&g p&day fork&s, of 10 dogs werrrtudd. anb 
serum (0.26 to 1.09 rrdrnl) and tissue (cardiac 2.97 to 11.60 
&mt) tweb of a&damne were mearored by liquid 
chmmatugraphy. 
Remodynamie measoremmts were made a, baroltneand 
after adminis,raLioo of routine Berapatic intravenous 
doses of dobutamine (IO Pg!%g pr mini, isapfo,erenol 
(0.06 ,@‘g per mi”) and epinophrine (I ,@i”,. The 
moiOdarone-trated dqs hwJ a ~mallvr increase in wrdiae 
oo,plt compared wi,h baseliw than did central dogs. For 
each drug when the amiodarone.treatrd group was corn. 
pared with the cimtrol group. increaw in cardiac output 
(litersimin) were: dobutmuine, 1.32 2 0.24 versus 1.73 * 
0.31: i~npr”trreno,. 0.84 * 0.26 wrws I.43 + 0.18: 
epinrphrine. Il.26 + 0.15 verse 0.44 r 0.53. Amiodarone- 
freafed dogs were also gkm higher dmes of drugs, d&o- 
tarnine (50 &kg per min). isoproter~rmt (1.1 @kg per 
min) and epieephriw (20 (Ipjmin). Increws in cardiac 
~u,put were I.24 t 0.24, 1.62 i: 0.U aad 2.82 C 0.64, 
rcsp&ively. All cardiac ootpub were significantly in- 
awsed from the bwliw values Ip < 0.05) except thoa 
mrasurcd in the amicdarmw gmop rvcriving Ihe lowtrdmc 
cf epinephrine. 
Thw, amicdarooe-treated dw have a r&t& redue- 
Lion of pvriopvrativc card& s)stolii reserve. Rew& OE 
this mjoeardial &pr&on may rewire the use uf dram in 
excess of standard dmes. Epincpbrinr was the mm, eec. 
live drug in ,hi sudy. I, pm&red improvements in 
cardiac ou,pu, Lq increasing rtrotx vohmx, *hemas 
chsnger rreondary lo dobotamnine or iroprotmrm! were 
more e&ty r&&d lo changes in hem-4 rate. The findings 
hare implicati%as for amio&mne-Iresled patienta during 
and after cardiipidmonary bypass. 
The clinical use of amiodarone. an eKec,ive oral &ass 111 
antiarrhythmic agent, is increasing in the United Srales. Thin 
benzofuran derivative is a noncompetitive beta-receptor 
blocking agent (I-1) with a long dumiion of action (>25 days 
half-life) (4.5). Amiodarone is a valuable therapeutic ilgent 
with known e&cts including prolongalion of atrial and 
ventricular action potential duration (01, coronary ui pr- 
ripheral arterial vasodilation (1.7.8) and atropinc-rcsintant 
bradycardia (9). Side rffecls 110.1 I) m&de pulmonary 
(IZ.I3). renal 114) and hcpatic (iS.lh) loxicily, cornea1 
microdcpocils (17). vasculilis (IS). hypenhymidism and hy- 
pothyroidism (19.20). neurologic disorders 121) and derma- 
litis Z2.23). In addition. Ihe possibility of myocardial de- 
prssaon from amiodarone is controversial, with wme 
repon of a depressant effect (7,9,24-37) and others dispur- 
ing such an effect (I +X37-4@. The? are repor& of increased 
perioperative marbidity and mortality m palientr receiving 
am!odarcne l25.28.41.42). but no caperimental demonstn- 
tion of both the oegatiw cardiac effects nfamiodamne and of 
the merhodx for their reversal exists. We hypothesized lhal 
amiodarone has B negative cardiac molropic effect that 
contributes ,o surgical complications, particularly during 
md after :srdiopulmonary bypass. Also. we hypothesized 
that ,ht efects cauld be reversed by very large do~cs of 
inotropic agonists. 
Twenty adult mongrel dogs ,I7 lo 27 kg) were separated 
into two groups. Ten dogs received I.5 r&kg body weight of 
oral amiodarone native powder ,Sanofe Research) daily for 
21 days. The other IO dogs received no drugs and served as 
a control g,roup. All animal3 were cared for undel the 
supervision of the vi&urn staBand veterinarians and were 
treated according to protocols approved by our institutional 
animal research :eview conmiutee. 
Experimental prepamtlon. All of the dogs were anesthe- 
tized with sodium pentobarbilal (30 mg/kg) and ventilated 
with a respirator lmodei 613. Harvard Apparatus Co.1 Sup- 
plemental’pen~obarbital WBE given as needed. The electro- 
cardiogram (KG). hematocrit. rerum potassium and arterial 
blood gases were monitored and maintained within physio- 
logic limits. 
A fluid-filled crtlheler was inserted into the dorsal aorta 
aad connected to a strain gauge (Statham P23-1D strain 
gauges, Gould Instruments) for the measuremenl of aortic 
pressure and a second Ruid~filled catheter was placed into 
the inferior vena saw (waler manometer. Medex Inc.) for 
measurement of central venous pressure. After a median 
slernotony. a catheter-duped micromanometer (?C-471, 
Millar Instruments) with anadditional fluid-filled lumen was 
directed into the left ventricle by way of the right superior 
puhnonary vein for the measurement of left ventricular 
pressure and calculation of maximal kft ventricular rate of 
Iire of prcsrurc ,dPidt). Thermodilution cardiac output and 
pulmonary artery ~reswre were detewined with a Suan- 
Ganr cathew &&can Edwards Laboratories) inserted 
through the left internal jugular vein (Fin. If. The pressures 
and ECG were recorded-o; a StriQ charirecorder iHewlett- 
Packard 7754A) (Fig. 2). The maximal left ventricular dP/& 
was calculated from the rate of rise of the left ventricular 
pressure tracing. The transducers were recalibmted at regu- 
lar imervals throughout the experiment Cardiac output 
determinations were performed in triplicate and means were 
caiculaled. Cowistency ,*S%l was the criterion for accept- 
abilitv of these determinations. 
Tihp following derived kcntody~wndc wnables WCTE cal- 
crdarcd: SV = COIHR: SVR = AoPICO: PVR = IPAP - 
LAPKO; LVSW = ,A;P - LVEDP) (O.dl44) (SVI; and Cl 
= COIBSA; where SV = stroke volume. CO = mean cardiac 
ouIpuI. HR = hear1 rate. SVR = wstemic vdscula resis- 
tance. AoP = mean pressure in the ao.orla, PVR = pulmonary 
vascular resistance, PAP = mean pressure m the pulmonary 
anery, LA? = mean pressure in the !eh atrium, LVSW = 
lell ventricular stroke work, LVEDP = left ventricular 
end-dlas:olic pressure, Cl = cardiac index and BSA = body 
surface area (43). 
Figure I. Diagram showing location of thdd-filled catheten for 
me~suremenr of pressures in the aorta ,A@, inferior VIM cave 
,IVC) and left an’ium (LA). A cathetwtipped micromanometer 
parsed anterograde across the mitral valve by way of the right 
superior pulmonary vein IRSPVI was used to measure l ft ventric- 
ular pressure &VP) and calculate mraimal eft ventricular ,LV) dP/ 
do. A Swan-‘Ianz catheter placed by way of the superior vena caw 
(SK) was used for determination f puhnonary artery preSsUreI 
(PAP) and cardiac output (CO). AoP = aortic pressure: CVP = 
central “e”o”s pressure: LAP = left atrial Q~.%S”~: PA = pulmonary 
awry: RA = righl atrium. 
Liquid ehmmntography. Serum was obtained from each 
of the amiodsrone-treated ogs beiore median sternotomy 
and was tested for levels of amiodarone and desethylamio- 
darone by liquid chnxnatogrnphy nsing established methods 
(44). After completion of the experiment, tissues were ob- 
tained from each dog and levels ofamiodarone and desethyl- 
amiodarone were determined for heart, lung, thyroid and 
kidney. Samples of 200 to 300 mg of each organ were 
homogenized in 2 ml of absolute methanol using a Sorval 
electric grinder (model PCU-2, Brinkman Instrument). The 
sampler were homogenized for 15 s and centrifuged at ISW 
‘pm for 15 min. Supernatant samples of I ml were removed, 
dried and reconstituled in I ml of acetonitrile. Further steps 
for drug extraction are idectical to those for serum. 
Infusion of lnutropic drugs. After the animals were inslru- 
mentrd and the baseline measurements performed. the re- 
sponses to routinely used therapeutic doses of each of the 
following agents were measured: isoproterenol ,Elkins-Sinn. 
Inc), 0.06 &kg per min; dobutamine (Eli Lilly 81 Co.), IO 
,ugikg per min: epinephrine (Elkins-Sinn. Inc.), 2 &mm. 
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Figure 2. Reptesentative tracings of control and high dox epincph- 
rine (20 &kg per mm) administration in an amiodamne-treated dog 
US mgikg per day for 3 weeks) In this example epmephrine did not 
change hemi rate (HR) by etectmcardiogram (ECG). but it did caux 
an increase in cardiac output ICOI by thermcdilution PS well as 
fm”iC pressure ~A0P,. left ventricular prerrure ,L.“P, and maxima, 
left ventricular dPldt, which uac calculated from the slope of the M 
ventricular pressure tracing. 
The drugs were infused by a pump (model 9131. Harvard 
Apparatus Co.) at a rate of 0.71 mllmin through the femoral 
vein. The appropriate drug dilutions were detemtmed using 
a hand-held reference calculator (TI-351 I, Texas lnrtru- 
merits, Inc.). 
Hemodynamic srobilifv WLIS w~l/y ochirved after IO min 
of infusion of each of the drugs and was confirmed by the 
stability of the aottic and pulmonary artery pressures. Ap- 
propriate time intervals of IO to 20 min were allowed after 
the cessation of each drug to avoid the residual etTect of any 
one drug. The order of administration of the drugs was 
alternated in successive experiments in both co&l and 
drug-treated dogs. New baseline readings were obtained 
between drug administration to assure the stability of the 
preparation. 
Factors that cordd afen ow results were carcfrrlly mca- 
sared and controlled in there mp.rprritnrn~s. These included 
arterial pH, PO,, Pco~. serum potassium. hematocrit and 
body temperature. Additionally, pentobarbilal. a potential 
myocardial depressant, was used as an anesthetic agent and 
could have altered ventricular function. After each dose of 
pentoharbm!. dogs *err. allowed ~10 mm to react, a ctnble 
hcmodynamic .state. The average total doses of pcntobarbttal 
(mgl were the same in the control and amiodaronc-trcatcd 
groups (mean 2 SE) II.381 + 98 wsus I.394 ? 62). 
Boih wqx of dogs were ~ivm rhr mm routine fheru- 
pesric darer of rhe rhree drrup, but the amiodamne-treated 
group also recaved higher doses of the sarrw drugs (isopro- 
terenol. I .? &kg per min; dobutamine. 50 &kg per min 
and epinephrine, 20 &mm). 
Data analycip. All measured and calculated variables 
were compared with baseline values immediately preceding 
a drug intervention and the differences were determined. 
Stat!stical analysis of the baseline values and mean diiTer- 
rncer was then performed. 
The spectfic differences between baseline values and 
experimentally altered values were identified by paired I 
statistics for individual treatment conditions. The likelihood 
of a type 1 error was minimized by requiting differences to 
c&l 1’1 zi !Lh,i ox i.G~-ioiil;:.%ilt c:.z%&cri-.::c L&z d* 
clanng a gwcn characteristic to be different from its baseline 
value. ‘This pattern of difference was considered to over- 
whelm the probability of randomly occurringdifferences thst 
met the statktical criterion. even in a small sample. Differ- 
ences among treatments were first detected by analysis of 
vanawe. and confimted and quantitalcd by differences 
between means and the accompanying I statistics. As with 
the paired statistics. pzttems of differences were sot& 
before deciding an the importance of individual differences. 
Values represent mean change 5 SE. Statistical significance 
was determmed by analysis of variance with p < 0.05. For 
changes in QT interval a Student’s t test for independent 
variables was used. A p value CO.05 was considered signif- 
icant. 
RMlltS 
Hemadynamic tneasarements. Table I lists the baseline 
hcmodynamic variables (mean 5 SE) for the control and 
amiadarane-treated groups. There were no statistically sip 
niticant baseline differences between the two groups. al- 
though a trend toward a lower cardiac output in the amic- 
darone group was noted. 
Table 2 lists the changes in all measured and calculated 
values between baseline readings just before a drug inter- 
vention and the value during drug intervention after herno- 
dynamic stability was reestablished. It is notable that at high 
doses of motmpic agents compared with standard doses. 
heart rate increased significantly for dohutamine and isopro- 
terenol. but not for epinepbrine. For epinephrine. in con- 
tmst, stroke volume increased significantly in comparing 
high and elandad doses. Tbe luger doses of epinephrine 
produced significant increases in cardiac output. whereas 
routinely used therapeutic doses of inotmpic agents ap- 
peared to have smaller effects (Table 3). 
Films 2 rrymdrrce~ rvprrsrnrariw rmcings wed Jar 
Iwmod~nomic ~wmu~m~m and compares recordings 
made in an amiodaronc-treated dog under contml and high 
dose cpincphrinc infusion conditions. Figure 3 illustrates the 
cardiac output increases caused by various doses of the 
three inotropic agents for the control and amiodamne- 
treated groups; Figure 4 illustrates the cardiac output 
Tahtc 3. lncrearcr in Cardiac Output lilerrimin t SEMI 
Produced by lnotropic D~gr 
changes caused by each drug. It is evident that amiodamne 
limits the cardiac output response to inotmpic agents and 
that epinephriw in increased doses produced the largest 
increase in cardiac output. 
Electrocardiographic nwwrements. Confirmation of the 
effect of amiodarone on the !reated animals was nn!ed by a 
statistically significant (Student’s t test for independent 
variables) (p < 0.05) prolongation of the QT interval of the 
electmcardiogram (mean + SE): 0.26 f 0.013 s versus 
contml of 0.22 f 0.0063 s, seen in Table 4. 
Liquid chmmatagraphy drug levels. Specific serum levels 
of amiodarone and desethylamicdarone in the treated dogs at 
the beginning of each experiment were measured by liquid 
chromatography and are listed in Table 5. Treated dogs had 
a serum concentration (&ml) of amicdarone (mean t SE) 
of 0.51 + 0.09 and of desethylamiodarone of 0.12 ? 0.02. 
Figure 3. Graph of change in cardiac OUtPUt YC‘S”S low and h,gh 
doses of inotropic agents in control and amicdamne-treated dogs. 
The wiodarone-treared dogs are lw rerpoxive rhan the control 
group to the inofmpic agents used. Error bsrr dsnole SE. 
Tissue levels of amiodamne and desethylamiodarone 
were also determined for heart, lung. liver, kidney and 
thyroid from tissue Sam&s harvested at the end of the 
e&iments. Levels for cardiac tissue with mean values 5 
slnndard error are listed in Table 5. Levels I&ml) for 
amiodamne and desethylamiodamne. respectively, for lis- 
sues other than heart were as follows (mean - SE): lung. 
40.52 * 9.25 and 47.11 i 10.85; liver, 4.12 + 0.95 and 3.90 
F 0.96; kidney, 4.46 * 0.70 and 3.78 : 0.68; thyroid. IOSQ 
? 1.70 and 2.48 2 0.55. 
There was a statistically significant correlation Ip < 0.05) 
FIgme A Graph of change in cardiac outpu! versus each spa& 
inotropic agent used in the experiment in control and amiodarone- 
treated ogs. Epinephrinc in high doses appears to he the most 
erTective agent in ami&rone.lreated ogs. Error bars denote SE. 
between serum amiodaronc and desethylamiodarone l vels 
and cardtac tissue levels of these drugs. Flowever. there was 
no slarwxaliy significant correlatxx between scrurn and 
tiswe levels of amiodarone or desethylamiwdarone and any 
of the baseline hemodynamic variables measured. A signif- 
icant correlation was found between tissue Ievels of amio- 
darane and changes in maximal left ventricular dP/dt pro- 
duced by high doses of dobutamine (p < 0.05). Similar 
co~~elatmns for changes in maximal left venlricular dP/dr 
produced by high doses of dohummine with serum lev& uf 
amiodarone 1 p = 0.065). serum levels of desethylamioda- 
rone Ip = 0.080) and lissue levels of desefhylamiodaronc (D 
= 0.058) marginally failed statistical significance 
Discussion 
This study suggests that amiodarone pmduces a decrease 
in cardiac function during surgical operations. This decrease 
is difficult 10 reverse using Ihe muline doses of cardiac 
inolropic agents. Larger doses of inolropic agents. pardcu- 
My epinephrine. however. did improve contractile function 
afthe myocardinrn and reversed the reduced cardiac systolic 
reserve produced by amiodarone. 
Baseline hemndynamie measnretnents nn nmindarone. 
These data provide support for the hypothesis that amioda- 
rone reduces baseline cardiac funclion. A trend toward 
decreased cardiac output and cardiac index in the amioda- 
rone-treated group was noted. but it did not reach statistical 
significance. Although amiodamne is thought to have vaso- 
dilatory effects. our dogs on long-term treatment with amio- 
darone had a trend toward increased pulmonary and sys- 
temic vascular resistance. This has been noted by others 
(9.28,34) and may indicate a compensatory chronic vasocon- 
striction with a chronically decreased cardiac output. No 
other significant differences between control and amioda- 
none-treated dogs for observed and calculated baseline he- 
modynamic variables were noted. These results are different 
from those of previous authors (9,28) who reported signift- 
cant decreases of maximal left ventricular dPidt and left 
ventricular stroke work when amiodarone-treated animals 
were compared with control animals under similar condi- 
tions and doses of amiodarone. This variance most likely 
reflects the large variability of cardiac function among mon- 
grel dogs. A recent rep&t (42) of a retrospective &diac 
surgical study noted. as we have, that postoperative low 
cardiac output was more cotnmon in amiodarone.treated 
than in untreated patients, but this difference was not 
statistically significant. Thus. although reports of a negative 
myocardial etTect ofamiodamne exist at baseline. it has been 
difficult to establish statistical significance. 
In this study. the experimental protocol reflects the 
difficulty of experiments in which treated dogs cannot serve 
as their own controls. Because ofthe long-tern, nature of our 
experiment and the need for extensive surgical manipula- 
tion, using dogs as their own controls was not practical. We 
perforated long-term experiments to avoid the controversy 
about the myocardisl depressant effects of amiodarone and 
the difference between short-term intravenous administra- 
tion and long-ternr oral dosage. The intravenous form of 
amiodarone is suspended in polysorbate 80. itself a myocar- 
dial depressant (26) that may contribute to the short-term 
depressive etfects of the intravenous amiodarone prepara- 
tion. To avoid the effects of polysorbate 80 we investigated 
only the effects of!ong-term oral amiodarone administration. 
Our dogs received amiodarone powder in pure form obtained 
from the manufacturer. Other factors that might have influ- 
enced our results were controlled carefully. These included 
PH. Pot, Pco,, hematocrit. serum potassium and tempera- 
ture. The dares of pentoharbital anesthetic were similar in 
both the control and experimentsl groups, and care was 
taken to avoid the short-term effects of this drug on our 
preparation. Another potential eanse for the lack of statisti- 
cally significant baseline di5crences between the two groups 
could be an inadequate dose of amiodarone or an inadequate 
duration of administration. However, others have used the 
same dosage regimen (IS mgikg per day) in dogs treated for 
only 2 weeks (9.28) ns opposed to our 3 weeks of adminis- 
tration and found significant hemodynamic etTccts. In addi- 
tion, we noted a statistically significant prolongation of QT 
interval, confirming an amiodarone drug effect in our dogs. 
On the basis of these data it would appear that long-terrtt 
amiodarone treatment produces a decrease in cardiac rys- 
tolic reserve that may have important implications for pa- 
tients who have preexisting, globally decreased left ventric- 
ular function, or whose heart has been depressed by 
cardiopulmonary bypass. 
Hemwlynamie tbangee prnduced by inolropic agents. To 
investigate methods for the reversal of en amiodarone- 
induced reduction in cardiac systolic reserve. both amioda- 
rone-treated and control groups were subjected to routinely 
used therapeutic doses of the inotmpic agents dobtttamine. 
isopmtercnol and epinepbtise. Changes in variables relative 
to predrug values were calculated. Statistically significant 
differences in cardiac output relative to the baseline values 
were found for all drug interventions except 2 f.tglmin of 
epinephrhte. Although increases in cardiac output using 
routine doses of inotropic drugs were smaller in the amioda- 
rone-treated dogs than in control dogs, these di5crcnces 
were not statistically significant. When high doses of dobu- 
[amine and isoproterenol were used in amiodarone-treated 
dogs, increases in cardiac output were noted that approxi- 
mated those produced by routine doses ofinotropic drugs in 
the contml dogs. However, these drugs produced signb%ant 
increases in heart rate and not in stroke volume. Thus the 
changes in cardiac output secondary to high doses of dobu- 
[amine and isaproterenol were predominantly rate related. 
In contrast, epinephrine in high doses not only produced a 
larger increase in cardiac output in the amiodarone-treated 
dogs than did dobutamine or isoproterenol, but increased 
cardiac output by increasing stroke volume and not heart 
rate. These rcsuhs substantiate empiric reports (9,25.28,32) 
that suggest the need to use higher doses of inotropic agents 
for postoperative support of patients treated with amioda- 
row. and they support published data on the beneficial 
effects of high dose epinephrine. 
Thhas, hrgr doses of inofropic agem were required to 
bnprow myocardial fmcrioa after rhr long-mm amioda- 
ram weatmenr of dogs. Epinephrhte in high doses was 
particularly effective in reversing the chronic myocardial 
effects of amiodarone. Epinephrine may be of significant 
clinical value for treating patients with decreased left ven- 
tricular function who are receiving amiodarone. 
Correlation with serum and lisaue amindamue levels. The 
serum and tissue levels of amiodarone and desethylamioda- 
rone varied widely among dogs. For each dog, however, 
serum and cardiac tissue levels correlated significantly (p < 
0.05). The serum levels of amiodarone and desethylamioda- 
none were in the lower range of values reported for long-term 
cky chosen 10 correspond wth the regimen previousI; wed 
in canine experiments (9.281. 
amiodamne administration IS.1 1.45.461. However. our dur- Intcd ~gndic~ntly, but generally cons~~tcot relations with 
ace regimen of amiodorone (IS mpikp per day) was soecifi- hemodvnamrc variables were ddhcu,, 10 d,<covcr. Tboi. we 
\uggcc\; (ha! reports of increared periopentive complications 
in putenr~ trcared with amiodarone may be related lo a 
decreased caiduc systolic reserve cawed by the drug. Large 
dam of inompic agents. particularly epinephrine. may 
have value in acutely reversing this decrease in myocardial 
systolic rcww These rerult~ may be of Ggoifiranre at the 
time of weaning amiodxone-treated patients from cardiopol- 
monary bypw. especially those with baseline left vemricu- 
iar dysfunction. 
in evaluating changes in hcmodynamic variablzr afwr 
inotmpic drug administration with amiodarone and deaerhy- 
lamiodarone levels. a correlalion between tissue levels of 
amiodaronc and maxima! left ventricular dP/dt was noted 
with use of high doses of dobutamine. A Gmilar correht~on 
with semm levels of amiadarone and dewthylamiodarone 
and tissue levels oidenethylamiodaroneJust failed slatntical 
significance. We postulate that these correlations occurred 
because dobotam~ne has primarily a specdic cardiac beta- 
adrenergic agonist effect that in large doses produced a 
we Ih;ml; orril*r* ttmwr rod ‘arole tloa&y for help ,n preparann ofIX 
mrnurci,p, and c,aie Harding la, *,n,tmce in pr&xing Ihe anwoii( WC 
change in maximal IeFt ventricular dP/dt dependent on levels *,x0 Ihrnk S”,‘” KEI.1, MO for rewevinl: ,hc ma”“.c‘iPI. 
ofamiodarone and desefhvlamiodarone in serum and tissue. 
Although some invesriga>ors (13.3446) suggert that the 
effects of amiodarone may be directly correlatei wtth the References 
tissue concentrations at a rteady state. other repons (47.48) 
relating dosage as well as serum and tissue levels of amio- 
I Charbe, R. Dellcur C. Baudire A. Chrdk, F. Phammlogy of mida- 
damne and desethvlamiodamne are cootroversnl. These 
mne m rn,lrnginal drug with il “CR bidogical prow hrz”eimn~eilorr- 
chvne IMU~:MO~_I~. 
repons have both.soggested (471 and disputed (48) any 
relation between serum levels of amiodaronc and deserhyla- 
miodorooe and their etlicacy and toxicity. Our dara do not 
show any generally consistent correlation between semm 
and tissue levels OF amiodarone and the hemodynamic ek 
Fats OF this agent despite the one statistic& significant 
correlation bet&en tissue levels oiamiodamne and changes 
produced in maximal left ventricolar dP/dt by high doses of 
iobutamine. 
Although the known noncompetitive beta-adrenergic 
blocking eiTects OF amiodarooe are sufficient to explain the 
reduction in cardiac systolic reserve that we observed under 
operative cooditioos in dogs, it is interesting to hypothesize 
about other potential mechanisms of action. Amiodarone 
interacts with thyroid hormone receptors (49) and hypothy- 
roidism sod hyperthymidism are complications of amioda- 
rooe treatment. Recently, postcardiopulmonary bypass 
myoeardial depression has been attributed to decreased 
levels OF thyroid hormone (50). It may be that the negative 
inotropic elects of amiodamne after termination OF cardio- 
pulmonary bypass are not only mediated by its beta.receptor 
blocking effect. but by its effectects on thyroid hormone recep- 
tor sites. 
Cooclwioos. Our data suggest a relative decrease in 
myoeardial systolic reserve in dogs receiving maintenance 
amiodarone therapy. Dogs treated with amiodarone exhib- 
ited a trend toward decreased cardiac output and were less 
responsive to inotropic agents thai; were control dogs. Large 
doses of dobutamine. isopmterenol and epinephrine were 
used to increase cardiac ootput. Large doses of epinephrine 
produced the greatest increase in cardiac output predomi- 
nantly by increasing stroke voIume. Serum and cardiac 
tissue levels of amiodarone and desethylamiodarone corre- 
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